Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ • Healthcare

$14.09

-$0.05 (-0.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$14.19

Previous Close$14.09

Day Range$13.54 - $14.3

Avg. Volume (3M)16.3M

Market Cap$6.3B

52 Week Range

$1.76$15.37

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$99.3M100%

Gross Profitminus cost of goods$55.7M56%

In plain terms: out of every $100 in revenue, Iovance Biotherapeutics, Inc. currently loses $48.

Fundamentals & Financials

Revenue (TTM)

$324.9M

Net Income (TTM)

-$289.5M

EPS (TTM)

-$0.73

ROA (TTM)

-31.62%

Current Ratio

4.35

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-13.8%Q3 2025-$0.33

+13.8%Q4 2025-$0.25

+18.2%Q1 2026-$0.18

0.0%Q2 2026-$0.19

+17.6%Q3 2026-$0.11

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Iovance Biotherapeutics, Inc. (IOVA) reports on November 5, 2026. Wall Street is looking for consensus EPS of -$0.086 on consensus revenue of $114.1 million. For trailing context, revenue grew +65.7% year over year last quarter. The company has beaten EPS in 4 of 8 most recent quarters.

View full earnings history

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a NASDAQ-listed biotechnology company in healthcare that develops cell-based cancer immunotherapies using a patient's own immune system to target cancerous cells. In FY2025, the company recorded $263.5 million in revenue. Its lead offerings are lifileucel and LN-145, both investigational therapies in the clinical development stage.

Name

Iovance Biotherapeutics, Inc.

CEO

Frederick G. Vogt

Website

www.iovance.com

Industry

Healthcare

Year Founded

2007

Employees

975

Today's Snapshot

AI-generated

The day ended with IOVA slightly lower at 14.09, while its sector was weaker. Iovance reported a 62.5% response rate for lifileucel, its cell therapy, in a final melanoma study. IOVA reports earnings on 5 November.

Trading Volume

Below 10d avg (10.3M)

7.6M

vs S&P 500 Today

Moderate Outperformance

+0.17%

Updated: October 23, 2026 at 20:13 UTC

Technical Indicators

4 Buy3 Neutral1 Sell

IOVA presents a bullish technical profile underpinned by a strong trend reading and supportive medium/long moving averages. ADX is well into strong‑trend territory, and most moving averages from the 20‑ to 200‑day frame sit beneath current levels, while RSI and MACD are constructive if not overbought. Volatility is elevated relative to the share price and on‑balance volume signals show divergence, tempering the view. Overall the technicals favor continuation of the advance amid higher volatility. Technical takeaway: Buy, driven by a strong trend and broad moving‑average support.

All signals

EMA (5 indicators)$6.55 - $14.17
Buy
RSI (14)59.32
Neutral
Stochastic %K (14, 3, 3)64.49
Neutral
MACD Level (12, 26)1.03
Neutral

Peers & Related Assets

BNTXBioNTech SE

$88.1-0.0%

IBRXImmunityBio, Inc.

$8.22-1.1%

IMNMImmunome, Inc.

$17.99-1.5%

REPLReplimune Group, Inc.

$11.46-4.4%

FATEFate Therapeutics, Inc.

$2.11+1.0%

GMABGenmab A/S

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.